Related Experiment Video
Updated: Jan 19, 2026

Manufacture of Concentrated, Lipid-based Oxygen Microbubble Emulsions by High Shear Homogenization and Serial Concentration
Published on: May 26, 2014
Topiroxostat influences circulating lipid concentrations in hyperuricemic patients
Objective:
Hyperuricemia is an independent risk factor for renal dysfunction, cardiovascular events, and gouty arthritis. Xanthine oxidoreductase (XOR) inhibitors inhibit uric acid (UA) production and may be treatment options for hyperuricemia patients. I aimed to evaluate the effects of topiroxostat on circulating lipid concentrations in patients with hyperuricemia.
Materials And Methods:
83 hyperuricemic patients taking topiroxostat were enrolled into this retrospective study.
Results:
Serum UA significantly decreased, total cholesterol (TC) decreased, and low-density lipoprotein cholesterol (LDL-c) decreased between baseline and 24 weeks.
Conclusion:
Topiroxostat may have the potential to lower serum UA, TC, and LDL-c concentrations in hyperuricemic patients.
Related Concept Videos
13:17Manufacture of Concentrated, Lipid-based Oxygen Microbubble Emulsions by High Shear Homogenization and Serial Concentration
08:12Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:03Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
07:32Rapid Isolation of Viable Circulating Tumor Cells from Patient Blood Samples
06:53Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

